SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (“Cidara”) (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced its plans to commence an underwritten public offering, subject to market and other conditions, to issue and sell $250.0 million of shares of its common stock. All of the shares are being offered by Cidara. In connection with the proposed offering, Cidara expects to grant the underw ...

Cidara Therapeutics, Inc. CDTX stock is trading over 90% higher on Monday with a session volume of 3.2 million compared to the average volume of 181.7K.On Monday, the company released topline results from its randomized, double-blind, placebo-controlled Phase 2b NAVIGATE trial evaluating CD388 for preventing seasonal influenza in healthy unvaccinated adults aged 18 to 64.The study met its primary endpoint, demonstrating a statistically significant prevention efficacy (PE) for each of three dose groups in in ...

NASDAQ: CDTX JUNE 2025 NAVIGATE Ph 2B June 23, 2025 Forward-looking Statements These slides contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "may," "will," "estimate," "plan", "anticipate," "expect," "potential," "could," "project," and similar expressions (including the negative thereof), are intended to identify forward-looking statements. Because such statements are subject to risks and uncertainties, actual results may differ materi ...

Cidara Therapeutics (CDTX) Update / Briefing June 23, 2025 08:30 AM ET Speaker0 Greetings. Welcome to Sadara Therapeutics announces positive top line results from its phase two b NAVIGATE trial evaluating CD388, a nonvaccine preventative of seasonal influenza. At this time, all participants will be in listen only mode. A question and answer session will follow today's formal presentation. Reminder, this conference is being recorded. At this time, I'll hand the conference over to Brian Ritchie with Investor ...

This is my 4th coverage of Cidara Therapeutics (NASDAQ: CDTX ). At the time of writing, CDTX is trading at around +90% since my last coverage. CDTX has always been a long-term investment for me as explained in prior articles, but the Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole ...

Cidara Therapeutics (CDTX) Update / Briefing May 22, 2025 10:00 AM ET Speaker0 Good morning, and welcome to the Sadara Therapeutics Investor Day. At this time, all attendees are in a listen only mode. A question and answer session will follow the formal presentations. As a reminder, this call is being recorded and a replay will be made available on the Sadara website following the conclusion of the event. I'd now like to turn the call over to Doctor. Jeff Stein, President and Chief Executive Officer of Sada ...

Summary of Cidara Therapeutics (CDTX) Conference Call Company Overview - Cidara Therapeutics is focused on developing CD388, a long-acting antiviral drug targeting influenza, utilizing its Cloudbreak platform technology [2][3] - CD388 is currently in a 5,000 subject Phase 2B study [3] Core Technology and Product - CD388 is a drug Fc conjugate (DFC), combining a potent small molecule inhibitor (zanamivir) with an Fc fragment of a human antibody, designed for extended half-life and high exposure [3][4] - The drug targets neuraminidase, an enzyme essential for influenza viral exit from cells, aiming to provide universal protection against all flu strains [5][6] - Unlike traditional vaccines, CD388 does not require annual manufacturing adjustments based on circulating strains, making it a potentially more stable option [6] Clinical Development and Efficacy - CD388 has shown a 57% placebo-adjusted efficacy in Phase 2A human challenge studies, indicating its effectiveness in preventing influenza proliferation [17][21] - The drug is designed to be administered once at the beginning of the flu season, providing long-term protection [5][15] - The Phase 2B study is expected to yield results that could be compared favorably against traditional vaccines, which have an average efficacy of about 40% [22] Regulatory and Market Considerations - The company is in alignment with the FDA regarding the statistical analysis plan for the Phase 2B study, which is crucial for evaluating the results [27][40] - Cidara is targeting high-risk and immunocompromised populations for Phase 3 trials, where traditional vaccines have low efficacy (0-20%) [40] Market Opportunity - The total addressable market (TAM) for CD388 is estimated to include approximately 50 million patients in the U.S. alone, with potential pricing similar to Bifortis at around $500 per injection [44][45] - This could translate into a multibillion-dollar commercial opportunity given the size of the target population and expected pricing [45] Financial and Operational Preparedness - Cidara ended Q1 with approximately $175 million in cash, which is expected to last until the end of 2027, absent the initiation of a Phase 3 study [46] - The company is exploring various financing options, including capital markets and structured financing, to support Phase 3 preparations [46] - Drug supply for Phase 3 is ready, with plans to assume the highest dose for the study [47] Additional Insights - The Phase 2B study is designed to assess the drug's ability to prevent severe influenza symptoms, which is a critical outcome for its success [18][19] - The company is preparing for potential challenges in the upcoming flu season, which could impact trial outcomes and timelines [24][38]

SAN DIEGO, May 15, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that it will host a virtual research and development (R&D) day on Thursday, May 22, 2025, from 10:00 to 11:30 AM ET. To register, click here. Frederick G. Hayden, MD, FACP, is a Stuart S. Richardson Professor Emeritus of Clinical Virology and Professor Emeritus of Medicine at the ...

Cidara Therapeutics (CDTX) Q1 2025 Earnings Call May 08, 2025 05:00 PM ET Company Participants Brian Ritchie - Managing DirectorJeffrey Stein - President & CEOSeamus Fernandez - Senior Managing DirectorJim Beitel - Chief Business OfficerNicole Davarpanah - Chief Medical Officer Conference Call Participants Eric Schmidt - Biotechnology AnalystGregory Renza - Director & Senior Analyst of Biotechnology Equity ResearchJoseph Stringer - Senior AnalystRoy Buchanan - Equity Research Analyst Operator Greetings. Wel ...

Cidara Therapeutics (CDTX) Q1 2025 Earnings Call May 08, 2025 05:00 PM ET Company Participants Brian Ritchie - Managing DirectorJeffrey Stein - President & CEOSeamus Fernandez - Senior Managing DirectorJim Beitel - Chief Business OfficerNicole Davarpanah - Chief Medical Officer Conference Call Participants Eric Schmidt - Biotechnology AnalystGregory Renza - Director & Senior Analyst of Biotechnology Equity ResearchJoseph Stringer - Senior AnalystRoy Buchanan - Equity Research Analyst Operator Greetings. Wel ...